We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

75 hedge funds and large institutions have $87.1M invested in Navidea Biopharmaceuticals Inc. in 2013 Q2 according to their latest regulatory filings, with 75 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

101% more call options, than puts

Call options by funds: $3.51M | Put options by funds: $1.74M

Holders
75
Holders Change
+75
Holders Change %
–
% of All Funds
2.44%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
75
Increased
–
Reduced
–
Closed
–
Calls
$3.51M
Puts
$1.74M
Net Calls
+$1.76M
Net Calls Change
+$1.76M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

NAVB Hedge Fund Activity: Q2 2013 in Review

75 of the 3,075 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q2 2013, worth a combined $87.1M.

Buyers outnumbered sellers: 75 funds opened new NAVB positions and 0 closed out — a net gain of 75 holders — while 0 added to existing stakes and 0 trimmed.

  • 75 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $87.1M of Navidea Biopharmaceuticals Inc. stock for Q2 2013.
  • 75 funds opened new Navidea Biopharmaceuticals Inc. positions in Q2 2013 and 0 closed out, a net change of +75 holders.

Based on aggregated 13F filings for Q2 2013.